The vast majority of women who have a bleeding disorder or are hemophilia carriers experience noticeable symptoms, such as…
Articles by Marisa Wexler, MS
People with hemophilia may be less likely to develop cardiovascular disease (CVD) — disorders of the heart and blood…
Nearly all men with moderate-to-severe hemophilia BÂ given the experimental gene therapy EtranaDez (etranacogene dezaparvovec) in the HOPE-B trial have…
More than 80% of the men with severe hemophilia A treated with the investigational gene therapy Roctavian (valoctocogene roxaparvovec) in…
Obizur (susoctocog alfa), a pig-derived replacement therapy, can be used to prevent bleeding in people with acquired hemophilia…
The European Medicines Agency (EMA) has approved an accelerated assessment request for etranacogene dezaparvovec, an experimental gene therapy for…
Monthly treatment with the investigational medication fitusiran can reduce bleeding in people with hemophilia A and B, with…
Amarna Therapeutics has secured €5 million (about $5.6 million) in new funding, which it plans to use for developing…
In the first clinical trial of the experimental therapy SIG-001 for hemophilia A, one patient developed scarring in the…
Preventive treatment with Hemlibra (emicizumab) is safe and can effectively prevent bleeds in people with mild or moderate…